Advanced search×

Turning a protein kinase on or off from a single allosteric site via disulfide trapping.

Proc Natl Acad Sci U S A 108(15):6056-61 (2011) PMID 21430264

There is significant interest in identifying and characterizing allosteric sites in enzymes such as protein kinases both for understanding allosteric mechanisms as well as for drug discovery. Here, we apply a site-directed technology, disulfide trapping, to interrogate structurally and functionally how an allosteric site on the Ser/Thr kinase, 3-phosphoinositide-dependent kinase 1 (PDK1)--the PDK1-interacting-fragment (PIF) pocket--is engaged by an activating peptide motif on downstream substrate kinases (PIFtides) and by small molecule fragments. By monitoring pairwise disulfide conjugation between PIFtide and PDK1 cysteine mutants, we defined the PIFtide binding orientation in the PIF pocket of PDK1 and assessed subtle relationships between PIFtide positioning and kinase activation. We also discovered a variety of small molecule fragment disulfides (

Version: za2963e q8za2 q8zb8 q8zce q8zdf q8ze3 q8zfd q8zg4

Similar articles you may find interesting…

  1. Protein fishing using magnetic nano-beads containing calmodulin site-specifically immobilized via an azido-group.

    J Biol Chem (2013) PMID 23653405

    We developed a novel method for capturing proteins which interact with a target protein. This method utilizes a protein containing a site-specifically incorporated 3-azidotyrosine (N3-Y) and FG beads for immobilization of the protein via the azido group. Using calmodulin (CaM) as the target protein,...
  2. Intrabodies as Neuroprotective Therapeutics.

    Neurotherapeutics (2013) PMID 23649691

    The process of misfolding of proteins that can trigger a pathogenic cascade leading to neurodegenerative diseases largely originates intracellularly. It is possible to harness the specificity and affinity of antibodies to counteract either protein misfolding itself, or the aberrant i...
  3. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.

    Expert Opin Investig Drugs (2013) PMID 23647051

    Cyclin-dependent kinases (CDKs) regulate cell cycle progression. Certain CDKs (e.g., CDK7, CDK9) also control cellular transcription. Consequently, CDKs represent attractive targets for anticancer drug development, as their aberrant expression is common in diverse malignancies, and CDK inhibition ca...